Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,323 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Anomalies Clear all
Completed Phase 1 Interventional

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

NCT00503490
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
MP-376 (Levofloxacin solution for Inhalation), placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

NCT00513682
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Ultrase® MT20
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 15, 2026, 4:48 PM EDT
Recruiting No phase listed Observational

Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease

NCT06985225
View directory record Official record
Conditions
Severe Asthma, COPD, Non-CF Bronchiectasis, Cystic Fibrosis (CF)
Interventions
Hyperpolarized 129 Xenon
Combination Product
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Survivorship in Lynch Syndrome Families

NCT01126840
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telephone Interview, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 15, 2026, 4:48 PM EDT
Completed No phase listed Observational

Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease

NCT04531189
View directory record Official record
Conditions
Wilson Disease
Interventions
Not listed
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
New Haven, Connecticut • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

NCT00457821
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 15, 2026, 4:48 PM EDT
Withdrawn Not applicable Interventional

Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

NCT05229640
View directory record Official record
Conditions
CF - Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease
Interventions
Fibroscan
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 15, 2026, 4:48 PM EDT
Completed No phase listed Observational

Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis

NCT00577252
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
13 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2009 · Synced Oct 15, 2026, 4:48 PM EDT
Completed No phase listed Observational

Observational Trial of the Longitudinal Effects of CFTR Modulator Drugs

NCT04353752
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Bone Marrow Failure Syndromes

NCT00176878
View directory record Official record
Conditions
Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
Interventions
Stem cell transplant, Fludarabine monophosphate, Total lymphoid irradiation, Busulfan, anti-thymocyte globulin
Procedure · Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 15, 2026, 4:48 PM EDT
Not listed No phase listed Observational

PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis

NCT02419989
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
6 Years to 99 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 15, 2026, 4:48 PM EDT
Not listed No phase listed Observational

Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath)

NCT04735952
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
3 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Phoenix, Arizona • Aurora, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 15, 2026, 4:48 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Belcesiran in Patients With AATLD

NCT04764448
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Belcesiran, Placebo
Drug · Other
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
La Jolla, California • Gainesville, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Recruiting No phase listed Observational

Rare CFTR Mutation Cell Collection Protocol (RARE)

NCT03161808
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
George Solomon
Other
Eligibility
17 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

NCT01560260
View directory record Official record
Conditions
Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor, Paraganglioma
Interventions
Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Palo Alto, California • Iowa City, Iowa • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 15, 2026, 4:48 PM EDT
Recruiting Not applicable Interventional

Balloon Inflation Time for Esophageal Strictures (BITES): A Randomized Multi-Center Study

NCT07100379
View directory record Official record
Conditions
Esophageal Atresia With Tracheo-esophageal Fistula, Esophageal Atresia, Esophageal Strictures
Interventions
Endoscopic Balloon Dilation
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia

NCT01468454
View directory record Official record
Conditions
Congenital Hyperinsulinism (CHI), Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Interventions
18 F-DOPA
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 15, 2026, 4:48 PM EDT
Completed No phase listed Observational

Genetics of Mammographic Appearances and Patterns (The GenMap Study)

NCT01160510
View directory record Official record
Conditions
Benign Breast Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 15, 2026, 4:48 PM EDT
Terminated Early Phase 1 Interventional

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

NCT04906382
View directory record Official record
Conditions
Lynch Syndrome, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma, Mismatch Repair Deficiency, Recurrent Endometrial Cancer, Metastatic Endometrial Cancer
Interventions
Biopsy, Carboplatin, Paclitaxel, Tislelizumab
Procedure · Drug · Biological
Lead sponsor
Floor Backes, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 15, 2026, 4:48 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Different Sports Supplements on Metabolism and Perceptual Responses During Distance Running

NCT03596788
View directory record Official record
Conditions
Anomalies Gastrointestinal
Interventions
Carbohydrate Beverage, Placebo Beverage
Dietary Supplement
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Standardized Treatment of Pulmonary Exacerbations II

NCT02781610
View directory record Official record
Conditions
Pulmonary Cystic Fibrosis
Interventions
Standard of care IV antibiotic(s)
Drug
Lead sponsor
Chris Goss
Other
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
57
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 15, 2026, 4:48 PM EDT
Completed Not applicable Interventional

The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis

NCT04684823
View directory record Official record
Conditions
Cystic Fibrosis, Adherence, Medication
Interventions
Patch Cap, Patch App
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 15, 2026, 4:48 PM EDT
Recruiting Phase 1 Interventional

Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection

NCT07275905
View directory record Official record
Conditions
Cystic Fibrosis (CF), Achromobacter Infection
Interventions
AchromoPhage
Biological
Lead sponsor
Ghady Haidar
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 4:48 PM EDT
Completed No phase listed Observational

Cough-Generated Aerosols of NTM in Cystic Fibrosis

NCT01815866
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
CF with culturable NTM
Procedure
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 15, 2026, 4:48 PM EDT